A RANDOMIZED TRIAL OF NAVELBINE PLUS CISPLATIN VERSUS MITOMYCIN C PLUS VINDESINE PLUS CISPLATIN IN TREATMENT OF PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER

Objective:To compare the response and side effects of the regimen NP (NVB+DDP) with MVP (MMC+VDS+DDP) in treatment of advanced non same cell lung cancer (NSCLC).Methods:A total of 65 cases with advanced NSCLC were randomly divided into trial group and the control group,repectively,received NP regimen or MVP regimen.Each patient received at least 2 cycles chemotherapy.The response and toxic effects were evaluated according to WHO criteria.Rusults:Overall response rate was 46.6 %(14/30) in the NP group,overall response rate was 37.1 %(13/35) in the MVP group,but the difference between the groups did not reach statistical significance ( P 0.05).The median survival time was 8.5 months in NP group,and 7.6 months in MVP group ( P 0.05).Myelotoxicity,nausea/vomiting and phlebitis was the most frequently observed toxic effects in the two groups.Conclusion:The results of this study demonstrated that NP regimen had a better efficacy than MVP regimen for NSCLC,and the toxicity was tolerable.